Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know
The drugmaker delivered its first-ever quarterly profit and trounced Wall Street top- and bottom-line estimates.
Ironwood Pharmaceuticals
IRWD
IRWD
$8.99
$0.06
0.7%
BATS BZX Real Time Price as of October 17, 2019, 11:11 a.m. EDT
View Interactive IRWD Charts
Ironwood Pharmaceuticals Inc. is an entrepreneurial pharmaceutical company that discovers develops and intends to commercialize differentiated medicines that improve patients’ lives.
News & Analysis: Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript
IRWD earnings call for the period ending June 30, 2019.
Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
An SEC filing shows an activist investor is building a sizable position in the company.
Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript
IRWD earnings call for the period ending March 31, 2019.
Why Ironwood's Shares Climbed 11.7% on Wednesday
The constipation kingpin reported fourth-quarter results that sparked investor interest.
Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript
IRWD earnings call for the period ending December 31, 2018.
Novartis May Beat Ironwood Pharmaceuticals to the Punch
Novartis may be on track to win FDA approval of a sickle disease drug before Ironwood.
Here's Why Ironwood Pharmaceuticals, Inc. Stock Slipped 13.2% in December
A safety scare during a clinical trial with the company's lead candidate was the culprit.
Is Ironwood's Growth About to Slow?
New competition could slow prescription growth for Linzess and take some of the luster off this small-cap biotech stock.
A David and Goliath Story: Can Small-Cap Synergy Pharmaceuticals Take on Ironwood Pharmaceuticals?
Has the success of Synergy Pharmaceuticals' plecanatide put Ironwood on the warpath?
